Skip to main content
. 2020 Mar 3;11(9):875–890. doi: 10.18632/oncotarget.27506

Figure 4. Comparable effects after BCL6 degradation and knock-out.

Figure 4

(A) WES protein analysis of BCL6 in SU-DHL-4 Cas9 cells after BI-3802 treatment (500 nM, 20 h). (B) Long-term proliferation assays with BCL6 sgRNA infected SU-DHL-4 Cas9 cells after DOX induction and BCL6 degrader treatment. (C) Caspase 3/7 activity and (D) cell cycle analysis after 4–10 days treatment with BI-3802 at the indicated concentrations. Data are shown as means ± SD of independent experiments (n = 2 – 6). * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001.